SGMO - Sangamo Therapeutics Inc Stock Price, Fair Value and News

0.64USD+0.03 (+4.92%)Market Closed

Market Summary

USD0.64+0.03

Market Closed

4.92%

SGMO Stock Price

View Fullscreen

SGMO RSI Chart

SGMO Valuation

Market Cap

132.8M

Price/Earnings (Trailing)

-0.4

Price/Sales (Trailing)

0.75

EV/EBITDA

-0.24

Price/Free Cashflow

-0.61

SGMO Price/Sales (Trailing)

SGMO Profitability

EBT Margin

-189.08%

Return on Equity

-578.61%

Return on Assets

-254.38%

Free Cashflow Yield

-164.27%

SGMO Fundamentals

SGMO Revenue

Revenue (TTM)

176.2M

Rev. Growth (Yr)

-92.5%

Rev. Growth (Qtr)

-78.27%

SGMO Earnings

Earnings (TTM)

-328.1M

Earnings Growth (Yr)

-332.29%

Earnings Growth (Qtr)

18.59%

Breaking Down SGMO Revenue

Last 7 days

14.3%

Last 30 days

23.1%

Last 90 days

-53.6%

Trailing 12 Months

-50.4%

How does SGMO drawdown profile look like?

SGMO Financial Health

Current Ratio

1.71

SGMO Investor Care

Shares Dilution (1Y)

20.77%

Diluted EPS (TTM)

-1.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	241.0M	218.5M	201.4M	176.2M
2022	112.7M	114.2M	112.1M	111.3M
2021	131.4M	137.7M	108.5M	110.7M
2020	107.4M	111.4M	147.2M	118.2M
2019	79.9M	76.0M	74.4M	102.4M
2018	45.8M	58.9M	70.7M	84.5M
2017	18.9M	23.4M	32.4M	36.6M
2016	30.0M	25.3M	19.6M	19.4M
2015	51.2M	49.2M	45.4M	39.5M
2014	27.6M	31.1M	37.8M	45.9M
2013	23.0M	25.4M	26.2M	24.1M
2012	11.4M	14.4M	17.5M	21.7M
2011	16.4M	11.3M	10.3M	10.3M
2010	0	21.7M	21.3M	20.8M
2009	0	0	0	22.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Sangamo Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 25, 2024	duraibabu prathyusha	sold (taxes)	-3,901	1.13	-3,453	svp, chief financial officer
Feb 25, 2024	pooler amy	sold (taxes)	-2,778	1.13	-2,459	vp, head of research
Feb 25, 2024	macrae sandy	sold (taxes)	-27,297	1.13	-24,157	president, ceo and director
Feb 25, 2024	willoughby scott b.	sold (taxes)	-3,901	1.13	-3,453	svp, gen. counsel & secretary
Feb 25, 2024	dubois-stringfellow nathalie	sold (taxes)	-5,661	1.13	-5,010	svp-chief development officer
Feb 24, 2024	willoughby scott b.	sold (taxes)	-4,948	1.13	-4,379	svp, gen. counsel & secretary
Feb 24, 2024	macrae sandy	sold (taxes)	-18,209	1.13	-16,115	president, ceo and director
Feb 24, 2024	dubois-stringfellow nathalie	sold (taxes)	-6,185	1.13	-5,474	svp-chief development officer
Feb 24, 2024	pooler amy	sold (taxes)	-2,496	1.13	-2,209	vp, head of research
Feb 24, 2024	duraibabu prathyusha	sold (taxes)	-6,185	1.13	-5,474	svp, chief financial officer

Which funds bought or sold SGMO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	unchanged	-	3,173	16,755	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	-3,284	10,038	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-74.98	-51,850	23,146	-%
May 15, 2024	Royal Bank of Canada	reduced	-89.39	-27,000	5,000	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	247,059	247,059	-%
May 15, 2024	JACOBS LEVY EQUITY MANAGEMENT, INC	reduced	-80.96	-419,036	128,644	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-1.58	130,581	740,489	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-24.64	-11,289	148,985	-%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	new	-	20,359	20,359	-%
May 15, 2024	D. E. Shaw & Co., Inc.	reduced	-34.51	-489,007	2,055,800	-%

Are Funds Buying or Selling SGMO?

Are funds buying SGMO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SGMO

No. of Funds

Unveiling Sangamo Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 05, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 13, 2024	vanguard group inc	7.10%	12,598,994	SC 13G/A
Feb 12, 2024	biogen inc.	75%	14,652,466	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	7.9%	14,095,865	SC 13G/A
Jan 22, 2024	state street corp	1.53%	2,708,368	SC 13G/A
Oct 10, 2023	wasatch advisors lp	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.57%	14,045,609	SC 13G/A
Feb 09, 2023	wasatch advisors inc	-	0	SC 13G/A
Feb 07, 2023	state street corp	5.97%	9,788,884	SC 13G/A

Recent SEC filings of Sangamo Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 30, 2024	8-K	Current Report
Apr 19, 2024	ARS	ARS
Apr 19, 2024	DEF 14A	DEF 14A
Apr 05, 2024	SC 13G/A	Major Ownership Report
Apr 03, 2024	PRE 14A	PRE 14A
Mar 25, 2024	424B5	Prospectus Filed
Mar 25, 2024	8-K	Current Report
Mar 13, 2024	10-K	Annual Report

Peers (Alternatives to Sangamo Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Sangamo Therapeutics Inc News

Latest updates

Sangamo Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	2,042,000	9,398,000	6,835,000	157,957,000	27,230,000	26,460,000	29,378,000	28,231,000	27,986,000	28,563,000	27,872,000	26,280,000	25,800,000	57,763,000	21,553,000	13,076,000	54,851,000	21,958,000	17,548,000	8,071,000
Operating Expenses	-18.9%	52,007,000	64,101,000	115,806,000	130,407,000	139,923,000	82,622,000	81,354,000	75,112,000	73,492,000	67,885,000	76,999,000	76,572,000	72,582,000	69,232,000	61,464,000	59,450,000	57,598,000	53,382,000	51,206,000	51,052,000	51,968,000
S&GA Expenses	-100.0%	-	13,099,000	13,918,000	16,014,000	18,136,000	16,443,000	16,238,000	15,093,000	14,908,000	16,084,000	14,501,000	16,486,000	16,148,000	16,874,000	16,177,000	17,927,000	16,119,000	15,053,000	14,918,000	14,597,000	17,118,000
R&D Expenses	-29.2%	35,891,000	50,706,000	57,089,000	63,046,000	63,216,000	66,179,000	65,116,000	60,019,000	58,584,000	51,801,000	62,498,000	60,086,000	56,434,000	52,358,000	45,287,000	41,523,000	41,479,000	38,329,000	36,288,000	36,455,000	34,850,000
EBITDA Margin	-29.2%	-1.82	-1.41	-1.18	-0.87	-0.47	-1.61	-1.49	-1.46	-1.49	-1.52	-1.04	-0.82	-	-	-	-	-	-	-	-	-
Income Taxes	136.0%	98,000	-272,000	1,270,000	-6,264,000	194,000	238,000	30,000	82,000	100,000	-73,500	100,000	24,000	262,000	108,000	237,000	-	-	-	-	-	-
Earnings Before Taxes	19.1%	-48,991,000	-60,567,000	-102,893,000	-120,770,000	21,327,000	-51,714,000	-53,125,000	-43,091,000	-43,919,000	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-26.7%	-1.89	-1.49	-1.26	-0.94	-0.53	-1.72	-1.59	-1.56	-1.58	-1.61	-1.11	-0.88	-	-	-	-	-	-	-	-	-
Net Income	18.6%	-49,089,000	-60,295,000	-104,163,000	-114,506,000	21,133,000	-51,973,000	-53,155,000	-43,173,000	-43,977,000	-37,488,000	-47,688,000	-47,174,000	-45,933,000	-40,604,000	-1,550,000	-35,929,000	-42,913,000	4,555,000	-27,307,000	-30,284,000	-42,150,000
Net Income Margin	-27.2%	-1.86	-1.46	-1.24	-0.91	-0.53	-1.73	-1.59	-1.51	-1.57	-1.61	-1.67	-0.98	-	-	-	-	-	-	-	-	-
Free Cashflow	8.5%	-48,663,000	-53,209,000	-50,037,000	-66,251,000	-76,500,000	-64,523,000	-58,031,000	-59,430,000	-61,814,000	-55,572,000	-64,627,000	-59,830,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-22.0%	129	165	220	325	441	563	594	617	654	722	772	835	877	939	964	895	584	638	640	673	543
Current Assets	-27.2%	69.00	94.00	148	160	227	300	337	343	340	399	447	554	607	660	700	679	371	405	384	462	363
Cash Equivalents	22.4%	55.00	45.00	57.00	67.00	78.00	100	95.00	118	120	180	177	170	123	133	259	467	86.00	82.00	114	169	81.00
Net PPE	-18.1%	22.00	27.00	28.00	61.00	60.00	64.00	56.00	53.00	52.00	52.00	51.00	50.00	45.00	41.00	35.00	34.00	31.00	30.00	27.00	21.00	18.00
Goodwill	-	-	-	-	-	-	38.00	35.00	37.00	39.00	40.00	41.00	42.00	41.00	43.00	41.00	39.00	39.00	39.00	38.00	40.00	39.00
Liabilities	-12.3%	72.00	82.00	85.00	91.00	105	268	285	299	320	347	366	390	408	441	443	383	190	205	221	228	214
Current Liabilities	-15.7%	40.00	48.00	48.00	54.00	58.00	112	122	120	119	128	132	137	133	144	124	94.00	62.00	70.00	81.00	82.00	91.00
Shareholder's Equity	-31.6%	57.00	83.00	135	234	336	295	309	318	335	375	406	445	469	497	521	511	394	433	419	446	329
Retained Earnings	-3.5%	-1,455	-1,406	-1,346	-1,241	-1,127	-1,148	-1,096	-1,043	-1,000	-956	-918	-871	-823	-777	-737	-735	-699	-656	-661	-634	-603
Additional Paid-In Capital	1.6%	1,516	1,492	1,486	1,480	1,467	1,450	1,423	1,373	1,340	1,334	1,324	1,313	1,292	1,269	1,256	1,248	1,097	1,091	1,084	1,079	934
Shares Outstanding	1.2%	180	178	177	174	169	167	151	147	146	145	145	144	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.94	-0.87	-0.53	-0.25	0.00	0.00	0.00	1.00	1.00
Float	-	-	-	-	229	-	-	-	633	-	-	-	1,734	-	-	-	1,262	-	-	-	1,245	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	3.7%	-48,663	-50,538	-47,293	-60,711	-66,300	-57,049	-53,618	-53,985	-58,975	-52,714	-59,420	-52,567	-68,550	-4,295	33,067	159,993	-18,890	-20,816	-38,874	-39,593	-45,119
Share Based Compensation	-55.5%	2,719	6,107	6,189	6,790	8,277	8,248	7,793	7,918	7,691	8,076	7,873	9,483	7,524	6,642	6,682	6,764	5,620	5,239	4,701	4,867	4,523
Cashflow From Investing	-5.0%	35,840	37,708	37,627	42,468	35,728	42,613	-13,462	28,429	1,705	52,635	60,976	89,299	45,289	-130,458	-242,497	77,608	23,720	-16,402	-16,217	-12,383	-14,799
Cashflow From Financing	13146.7%	22,122	167	-100	6,519	8,002	19,535	43,818	22,874	-1,567	2,112	5,492	10,019	15,235	6,919	1,616	144,156	409	1,219	704	139,890	216

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SGMO Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Revenues	$ 481	$ 157,957
Operating expenses:
Research and development	35,891	63,216
General and administrative	11,767	18,136
Impairment of long-lived assets	4,349	20,433
Impairment of goodwill	0	38,138
Total operating expenses	52,007	139,923
(Loss) income from operations	(51,526)	18,034
Interest and other income, net	2,535	3,293
(Loss) income before income taxes	(48,991)	21,327
Income tax expense	98	194
Net (loss) income	$ (49,089)	$ 21,133
Net (loss) income per share
Basic (in dollars per share)	$ (0.27)	$ 0.13
Diluted (in dollars per share)	$ (0.27)	$ 0.12
Shares used in computing net (loss) income per share
Basic (in shares)	180,342	168,533
Diluted (in shares)	180,342	169,181

SGMO Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 54,417	$ 45,204
Restricted cash	916	0
Marketable securities	0	35,798
Accounts receivable	691	923
Prepaid expenses and other current assets	12,612	12,403
Total current assets	68,636	94,328
Property and equipment, net	22,017	26,874
Operating lease right-of-use assets	20,935	25,991
Refundable research income tax credits and other non-current assets	17,373	16,627
Restricted cash	0	1,500
Total assets	128,961	165,320
Current liabilities:
Accounts payable	15,468	15,259
Accrued compensation and employee benefits	6,300	8,918
Other accrued liabilities	18,474	23,554
Total current liabilities	40,242	47,731
Long-term portion of lease liabilities	30,817	33,515
Other non-current liabilities	1,205	1,187
Total liabilities	72,264	82,433
Commitments and contingencies
Stockholders’ equity:
Preferred stock	0	0
Common stock	2,037	1,781
Additional paid-in capital	1,515,926	1,492,077
Accumulated deficit	(1,455,465)	(1,406,376)
Accumulated other comprehensive loss	(5,801)	(4,595)
Total stockholders’ equity	56,697	82,887
Total liabilities and stockholders’ equity	$ 128,961	$ 165,320

About Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

CEO	Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
WEBSITE	sangamo.com
INDUSTRY	Biotechnology
EMPLOYEES	478

Sangamo Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Sangamo Therapeutics Inc? What does SGMO stand for in stocks?

SGMO is the stock ticker symbol of Sangamo Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Sangamo Therapeutics Inc (SGMO)?

As of Fri May 17 2024, market cap of Sangamo Therapeutics Inc is 132.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SGMO stock?

You can check SGMO's fair value in chart for subscribers.

What is the fair value of SGMO stock?

You can check SGMO's fair value in chart for subscribers. The fair value of Sangamo Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Sangamo Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SGMO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Sangamo Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SGMO is over valued or under valued. Whether Sangamo Therapeutics Inc is cheap or expensive depends on the assumptions which impact Sangamo Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SGMO.

What is Sangamo Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, SGMO's PE ratio (Price to Earnings) is -0.4 and Price to Sales (PS) ratio is 0.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SGMO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Sangamo Therapeutics Inc's stock?

In the past 10 years, Sangamo Therapeutics Inc has provided -0.26 (multiply by 100 for percentage) rate of return.